The RAVEN trial offers hope to children with relapsed or refractory acute lymphoblastic leukaemia

The RAVEN trial offers hope to children with relapsed or refractory acute lymphoblastic leukaemia

We are very pleased to announce that Snowdome, in conjunction with the Leukaemia Foundation, are funding RAVEN, a new, national paediatric trial for Australian children with relapsed or refractory acute lymphoblastic leukaemia (ALL). This is the first study of its kind to look at the effectiveness of a combination treatment to overcome chemotherapy resistance in children and young people with relapsed ALL. This trial aims to bring hope to the families and new treatment options for children suffering from ALL.

You can learn more here: RAVEN- Media Release

Leave a Reply